This bill extends federal support for bioindustrial manufacturing to include the production of active pharmaceutical ingredients, which are the key chemical components in medicines. The legislation amends an existing 2023 defense law to broaden the scope of federally-supported research and development programs from general industrial chemicals to also cover pharmaceutical manufacturing. The bill would allow the government to support the production of both the active pharmaceutical ingredients themselves and the key starting materials needed to make them. This change affects pharmaceutical manufacturers and suppliers who may become eligible for federal assistance with bioindustrial manufacturing processes. The legislation does not specify new funding amounts or timelines, but rather modifies existing federal support programs under the 2023 National Defense Authorization Act.